Evoke Pharma (EVOK) Competitors $4.43 -0.16 (-3.49%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$4.56 +0.13 (+2.93%) As of 07/25/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. ENLV, FBLG, NRSN, OVID, SONN, RANI, NNVC, ALXO, TPST, and TENXShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include Enlivex Therapeutics (ENLV), FibroBiologics (FBLG), NeuroSense Therapeutics (NRSN), Ovid Therapeutics (OVID), Sonnet BioTherapeutics (SONN), Rani Therapeutics (RANI), NanoViricides (NNVC), ALX Oncology (ALXO), Tempest Therapeutics (TPST), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. Its Competitors Enlivex Therapeutics FibroBiologics NeuroSense Therapeutics Ovid Therapeutics Sonnet BioTherapeutics Rani Therapeutics NanoViricides ALX Oncology Tempest Therapeutics Tenax Therapeutics Enlivex Therapeutics (NASDAQ:ENLV) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations. Which has more volatility & risk, ENLV or EVOK? Enlivex Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Evoke Pharma has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Does the media prefer ENLV or EVOK? In the previous week, Enlivex Therapeutics had 1 more articles in the media than Evoke Pharma. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 2 mentions for Evoke Pharma. Evoke Pharma's average media sentiment score of 0.93 beat Enlivex Therapeutics' score of 0.63 indicating that Evoke Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evoke Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ENLV or EVOK? Enlivex Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 791.27%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Evoke Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Evoke Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in ENLV or EVOK? 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 2.3% of Evoke Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is ENLV or EVOK more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Evoke Pharma's net margin of -43.80%. Enlivex Therapeutics' return on equity of -57.67% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Enlivex TherapeuticsN/A -57.67% -50.52% Evoke Pharma -43.80%-101.91%-33.75% Which has better earnings and valuation, ENLV or EVOK? Evoke Pharma has higher revenue and earnings than Enlivex Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.70Evoke Pharma$10.25M0.64-$5.35M-$2.87-1.54 SummaryEnlivex Therapeutics beats Evoke Pharma on 11 of the 16 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$3.90B$5.75B$9.55BDividend YieldN/A1.21%4.71%4.01%P/E Ratio-1.545.6720.8516.92Price / Sales0.6411.99461.42104.42Price / CashN/A6.4636.1858.54Price / Book0.932.798.655.87Net Income-$5.35M-$109.62M$3.25B$258.89M7 Day Performance-2.85%5.55%4.30%3.70%1 Month Performance67.80%12.34%10.57%11.71%1 Year Performance-26.33%17.01%35.68%17.98% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma1.2319 of 5 stars$4.43-3.5%N/A-23.4%$6.61M$10.25M-1.544News CoverageGap DownENLVEnlivex Therapeutics2.7969 of 5 stars$1.23flat$10.00+713.0%-19.3%$29.09MN/A-1.8670News CoverageAnalyst ForecastGap UpFBLGFibroBiologics3.8053 of 5 stars$0.72+3.3%$13.00+1,705.6%-85.8%$28.57MN/A-3.4310Positive NewsGap UpNRSNNeuroSense Therapeutics2.7032 of 5 stars$2.03+2.5%$14.00+589.7%+150.6%$27.75MN/A-3.7610OVIDOvid Therapeutics4.7409 of 5 stars$0.39+6.0%$3.13+701.3%-41.7%$27.73M$548K-1.1160SONNSonnet BioTherapeutics3.9574 of 5 stars$8.61-11.9%$20.00+132.3%-41.3%$27.26M$1M0.0010Positive NewsGap DownHigh Trading VolumeRANIRani Therapeutics2.4887 of 5 stars$0.41-3.9%$7.33+1,688.6%-81.5%$25.92M$1.03M-0.41110Positive NewsGap UpHigh Trading VolumeNNVCNanoViricides0.3505 of 5 stars$1.60+9.6%N/A-24.0%$25.72MN/A-2.2220High Trading VolumeALXOALX Oncology3.8437 of 5 stars$0.47+0.1%$3.30+606.6%-91.4%$24.94MN/A-0.1940Positive NewsTPSTTempest Therapeutics2.3277 of 5 stars$6.67-0.3%$30.00+349.8%-65.3%$24.56MN/A-0.3720Positive NewsTENXTenax Therapeutics1.8027 of 5 stars$5.85-1.7%$17.50+199.1%+82.2%$24.28MN/A-2.369Positive News Related Companies and Tools Related Companies ENLV Alternatives FBLG Alternatives NRSN Alternatives OVID Alternatives SONN Alternatives RANI Alternatives NNVC Alternatives ALXO Alternatives TPST Alternatives TENX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredIt’s my duty to share the “truth” I see behind this bible verseFormer CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVOK Stock Alerts